Melanotan II Peptide Calculator

Melanotan II (MT-2) is a synthetic cyclic heptapeptide analog of the endogenous alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino acid neuropeptide derived from proopiomelanocortin (POMC) cleavage. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The defining structural modification is a lactam bridge—a cyclic amide bond formed between the aspartate side chain carboxyl group and the lysine side chain amine—that constrains the peptide into a rigid, receptor-favorable conformation. This lactam-bridged cyclic structure confers enhanced metabolic stability and significantly increased receptor binding potency compared to the native linear alpha-MSH sequence.

MT-2 has a molecular weight of approximately 1,024 Da. It was originally developed at the University of Arizona as part of the Melanotan research program, which aimed to identify photoprotective agents capable of stimulating melanogenesis without requiring UV exposure. During preclinical studies, researchers observed potent off-target effects at melanocortin receptor subtypes beyond MC1R—findings that shifted MT-2 research toward its broader pharmacological profile. Using a Melanotan II calculator is essential for preparing this high-potency compound accurately; small volumetric errors translate to disproportionately large dose deviations.

MC1R: Melanogenesis Pathway

MT-2's most extensively characterized activity is at the melanocortin-1 receptor (MC1R), expressed predominantly on epidermal melanocytes. MC1R is a Gs protein-coupled receptor; agonist binding activates adenylyl cyclase, elevating intracellular cyclic AMP (cAMP) levels. This cAMP surge activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein). CREB drives expression of MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. MITF upregulates tyrosinase, TRP-1, and TRP-2—the rate-limiting enzymes of eumelanin synthesis—resulting in the pigmentation darkening observed in MT-2-treated animal models.

MC4R: Central Pathways in Research Models

MT-2 exhibits significant agonist activity at the melanocortin-4 receptor (MC4R), expressed widely in the CNS—particularly in the paraventricular nucleus of the hypothalamus and limbic structures. MC4R activation suppresses neuropeptide Y (NPY) and agouti-related peptide (AgRP) signaling, producing dose-dependent reductions in food intake and body weight in rodent models. In limbic and spinal cord circuits, MC4R and MC3R activation modulates the dopaminergic reward pathway and sexual motivation behavior—observations that prompted development of PT-141 (bremelanotide), engineered to isolate this central activity profile.

MC3R and MC5R: Secondary Receptor Activity

MT-2 also activates MC3R (expressed in the hypothalamus and peripheral tissues) and MC5R (expressed in exocrine glands and immune cells). MC3R involvement is implicated in energy homeostasis regulation and cachexia models. MC5R activation in exocrine glands affects sebaceous secretion and has been investigated in inflammatory skin disease models. These secondary receptor activities contribute to the broad biological profile observed in MT-2 research, reinforcing the importance of precise Melanotan 2 dosage control using the calculator above.

Standard Research Vial and Melanotan II Dosage Chart

The 10mg vial is the standard MT-2 research format. Because of MT-2's high receptor potency, preparation concentration is a critical variable—small errors in BAC water volume result in significant dose inaccuracies. Use the Melanotan II calculator above before drawing any dose.

Step-by-Step Reconstitution Protocol

1. 1Remove the MT-2 vial from cold storage and allow 15-20 minutes to reach room temperature in subdued lighting. Do not accelerate warming under running water or on a heat surface.
2. 2In reduced light conditions, disinfect the rubber stopper with a 70% isopropyl alcohol swab and allow to air dry. Minimize MT-2's exposure to ambient light from this point forward.
3. 3Using the Melanotan II calculator above, determine your target BAC water volume. For doses below 500mcg, prepare at 3ml BAC water per 10mg vial.
4. 4Insert the needle bevel-up against the inner glass wall. Inject BAC water in a slow, controlled stream. MT-2's cyclic structure is more resilient than linear peptides but remains susceptible to interface denaturation under aggressive injection.
5. 5Cap the vial, wrap immediately in aluminum foil, and gently roll between palms for 30-60 seconds. The solution should be clear and colorless. Refrigerate at 2-8 degrees C in a light-excluding container.

Early MT-2 melanogenesis research established a biphasic dosing paradigm that remains a reference framework in contemporary alpha-MSH analog studies. The rationale is based on melanocyte receptor saturation kinetics: MC1R internalization following sustained agonist exposure reduces surface receptor density over time. A higher-frequency loading phase achieves initial melanocyte activation and establishes a baseline pigmentation response, after which a lower-frequency maintenance phase sustains the effect with reduced receptor downregulation pressure.

For researchers studying side-effect thresholds—particularly nausea and facial flushing, mediated by central melanocortin and peripheral vascular mechanisms respectively—low-dose titration from the initiation of the loading phase is critical. Published rodent models typically begin MT-2 administration well below the receptor saturation threshold, incrementally increasing across administrations to establish the dose-response boundary for each observed effect. This approach requires precise volumetric accuracy at each step, making the Melanotan II calculator an indispensable tool for protocol reproducibility.

Despite being a compound that promotes UV-protective pigmentation in research models, Melanotan II is itself highly sensitive to UV light once in solution. The aromatic residues in MT-2's sequence—His (imidazole ring), D-Phe (phenyl group), Arg, and Trp (indole ring)—are all susceptible to UV-induced photooxidation. Tryptophan is particularly vulnerable: the indole ring undergoes rapid oxidation to kynurenine and N-formylkynurenine under UVA/UVB exposure, irreversibly inactivating the peptide.

• Lyophilized powder at -20 degrees C: Stable for 18-24 months when protected from light and moisture. The cyclic structure provides moderate resistance to dry-state degradation.
• Lyophilized powder at 2-8 degrees C: Acceptable for up to 6 months. Maintain away from fluorescent lighting.
• Reconstituted solution at 2-8 degrees C in the dark: Use within 28-30 days. Wrap vials in aluminum foil immediately after reconstitution.
• UV/ambient light exposure: Even brief exposure to laboratory fluorescent lighting can degrade Trp residues in reconstituted MT-2 within hours. Tryptophan oxidation produces a faint yellow discoloration—if observed, discard the vial.
• Temperature above 25 degrees C: The lactam bridge is more heat-stable than linear peptide bonds but will hydrolyze at sustained elevated temperatures.
• Freeze-thaw cycles (reconstituted): Contraindicated. Ice crystal mechanical shear can disrupt the cyclic structure and promote aggregation.

Why does Melanotan II cause nausea in some research models?

Nausea in MT-2-treated animal models is primarily attributed to MC4R and MC3R activation in the area postrema (AP) and nucleus tractus solitarius (NTS)—brainstem structures that integrate emetic signaling and lie outside the blood-brain barrier, making them directly accessible to circulating peptides. The area postrema functions as the brain's chemoreceptor trigger zone; melanocortin receptor activation here triggers the same downstream signaling pathways that emetic stimuli activate through 5-HT3 and D2 receptors. Dose-dependent nausea in MT-2 research models is consistently more pronounced at higher concentrations and during the loading phase. Titration from lower starting concentrations, facilitated by the 3ml BAC water preparation, is the standard methodological approach for characterizing the nausea threshold.

Does Melanotan II affect existing moles or freckles during studies?

Existing pigmented lesions—including nevi and ephelides—contain higher baseline concentrations of melanocytes with pre-activated melanogenic machinery. Because these cells already express elevated levels of MITF, tyrosinase, and melanin precursor enzymes, MC1R stimulation by MT-2 produces a proportionally amplified pigmentation response in existing lesions compared to surrounding normal skin. In rodent models with induced nevi, MT-2 administration consistently results in measurable darkening of pre-existing lesions at concentrations below those required for equivalent darkening in uninvolved skin. Baseline lesion mapping and photodocumentation are recommended components of any MT-2 melanogenesis study design.